1. Home
  2. NAMSW vs ATLCP Comparison

NAMSW vs ATLCP Comparison

Compare NAMSW & ATLCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • ATLCP
  • Stock Information
  • Founded
  • NAMSW N/A
  • ATLCP N/A
  • Country
  • NAMSW Netherlands
  • ATLCP United States
  • Employees
  • NAMSW 29
  • ATLCP 386
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • ATLCP Finance: Consumer Services
  • Sector
  • NAMSW Health Care
  • ATLCP Finance
  • Exchange
  • NAMSW Nasdaq
  • ATLCP Nasdaq
  • Market Cap
  • NAMSW N/A
  • ATLCP N/A
  • IPO Year
  • NAMSW N/A
  • ATLCP N/A
  • Fundamental
  • Price
  • NAMSW $8.35
  • ATLCP $23.20
  • Analyst Decision
  • NAMSW
  • ATLCP
  • Analyst Count
  • NAMSW 0
  • ATLCP 0
  • Target Price
  • NAMSW N/A
  • ATLCP N/A
  • AVG Volume (30 Days)
  • NAMSW N/A
  • ATLCP N/A
  • Earning Date
  • NAMSW N/A
  • ATLCP N/A
  • Dividend Yield
  • NAMSW N/A
  • ATLCP N/A
  • EPS Growth
  • NAMSW N/A
  • ATLCP N/A
  • EPS
  • NAMSW N/A
  • ATLCP N/A
  • Revenue
  • NAMSW N/A
  • ATLCP N/A
  • Revenue This Year
  • NAMSW N/A
  • ATLCP N/A
  • Revenue Next Year
  • NAMSW N/A
  • ATLCP N/A
  • P/E Ratio
  • NAMSW N/A
  • ATLCP N/A
  • Revenue Growth
  • NAMSW N/A
  • ATLCP N/A
  • 52 Week Low
  • NAMSW N/A
  • ATLCP N/A
  • 52 Week High
  • NAMSW N/A
  • ATLCP N/A
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 40.68
  • ATLCP 55.58
  • Support Level
  • NAMSW $9.40
  • ATLCP $22.04
  • Resistance Level
  • NAMSW $10.14
  • ATLCP $23.37
  • Average True Range (ATR)
  • NAMSW 0.33
  • ATLCP 0.35
  • MACD
  • NAMSW -0.12
  • ATLCP -0.00
  • Stochastic Oscillator
  • NAMSW 0.00
  • ATLCP 74.55

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About ATLCP Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share

Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.

Share on Social Networks: